The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Nailderm 250 mg Tablets

McDermott Laboratories Ltd., T/A Gerard LaboratoriesPA0577/068/001

Main Information

Trade NameNailderm 250 mg Tablets
Active SubstancesTerbinafine hydrochloride
Dosage FormTablet
Licence HolderMcDermott Laboratories Ltd., T/A Gerard Laboratories
Licence NumberPA0577/068/001

Group Information

ATC CodeD01BA Antifungals for systemic use
D01BA02 terbinafine


License statusAuthorised
Licence Issued17/06/2005
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back